COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 3 FDA records to the applicant name Lung Bioengineering, Inc.. It includes 1 original PMA approval. 2 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jun 22, 2026 to Oct 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PHO appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240033, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910. Recorded on P240033/S001, decision dated Oct 16, 2026.
Device categories in this collection
Normothermic Preservation System For Transplantation Of Initially Unacceptable Donor Lungs.
Changes described in PMA records
The FDA record lists decision APPR dated 2026-10-16 for supplement P240033/S001, a Normal 180 Day Track No User Fee submission whose reason is 'Postapproval Study Protocol.' The statement describes approval of the protocol for the post-approval study, submitted to comply with conditions of approval in the order for P240033. The changed item is a study protocol document, not the device's original approval; the S001 identifier ties it to PMA P240033 for a normothermic preservation system for transplantation of initially unacceptable donor lungs.
The statement reports the protocol's purpose as satisfying approval conditions, which is not independent proof of safety or clinical effectiveness. Absent details include the study design, endpoints, sample size, follow-up duration, and the specific conditions the protocol addresses; the source does not supply them. The specialty fields list Gastroenterology, Urology, while the device category describes lung transplantation, and the record does not reconcile that.
FDA approval-order wording
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240033.
Oct 16, 2026 · Normal 180 Day Track No User FeeThe FDA database entry P240033/S002 records approval of a post-approval study (PAS) protocol for the LungFX device, submitted on the normal 180 day track with no user fee. The stated purpose is to comply with conditions of approval in the original P240033 order; this supplement does not re-approve the whole system or add an indication. The listed device category describes the original scope: a normothermic preservation system for transplantation of initially unacceptable donor lungs, with product code PHO and applicant Lung Bioengineering, Inc.
The entry does not state the protocol's study design, endpoints, sample size, follow-up duration, or the specific approval conditions it addresses. It also records no safety or effectiveness findings, and the compliance statement is not independent evidence of clinical benefit. The specialty fields list Gastroenterology, Urology, which the supplied text does not explain relative to the lung preservation scope.
FDA approval-order wording
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240033.
Oct 16, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: This device (LungFX) is indicated for centralized, ex vivo (outside the body) evaluation of deceased-donor lungs (single and double) that cannot be placed for transplantation by an Organ Procurement Organization (OPO) with any of the matched candidates if using direct-to-recipient procurement and preservation procedures. LungFX provides normothermic perfusion and ventilation of procured donor lungs initially stored with cold static preservation solution.LungFX is intended to allow for re-assessment, in a controlled environment, of procured donor lungs suitability for transplantation into male and female patients aged 18 years or older with end-stage lung disease awaiting first time (double or single) lung transplantation. Lungs accepted for transplantation after LungFX require a second period of storage with cold static preservation solution, and cumulative preservation time of transplanted lungs is not intended to exceed 20 hours.
Jun 22, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.